ArticleFrontiers in oncology2025
Chemotherapy-induced alterations in miRNA expression and their prognostic implications in ovarian cancer.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Chemotherapy driven alterations in NK cell receptors and ligands in high grade serous ovarian cancer.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Ovarian cancer has a high mortality rate due to late diagnosis, relapse and chemoresistance. miRNAs play a major role in tumorigenesis as well as chemoresistance. Hence, we undertook a study, to evaluate the differential expression of miRNAs in clinical specimens of ovarian cancer patients that may highlight the effect of chemotherapy and their role in predicting survival outcomes. Methods: Clinical specimens were collected from n=127 participants comprising chemo-naive, chemo-treated ovarian cancer patients and healthy women as controls for the study. miRNA expression was evaluated by quantitative real-time PCR analysis. Results: Our results indicate an upregulation of miR-182 and miR-130a in the serum of treated ovarian cancer patients, which may be an effect of chemotherapy. Tissue levels of miR-182 and miR-106a were elevated in patients with advanced-stage disease. Elevated tissue expression of miR-106a was also associated with poor chemotherapy response and early relapse, while miR-200a was elevated in metastatic patients and linked to early relapse. However, reduced tumor suppressor miR-433 and miR-145 levels were observed in metastatic patients. Multivariate Cox regression identified serum miR-130a and tissue miR-20a as independent predictors of progression-free survival. A combined serum miRNA panel (miR-182, miR-106a, miR-23b) demonstrated diagnostic potential with an AUC of 0.743. Conclusion: The study highlights differential regulation of circulating and tissue miRNAs in Indian OC patients, emphasizing the selective retention of oncogenic miRNAs in tumors and release of tumor suppressive miRNAs into circulation. These findings support the utility of miRNAs as diagnostic and prognostic biomarkers in OC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.